Status:
COMPLETED
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
Lead Sponsor:
Pfizer
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
Brief Summary
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
Eligibility Criteria
Inclusion
- 30- 80-year-old PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn \& Yahr stage score of 2-5 in the "off" state.
Exclusion
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00163085
Start Date
May 1 2005
End Date
January 1 2006
Last Update
September 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Portland, Oregon, United States, 97239